Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.55 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.45 |
| ▸ | WIZ | O95785 | 1/20 | 0.44 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413754 | 0.89 | CRBN (0.58) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413676 | 0.88 | CRBN (0.60) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL60743 | 0.87 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL24821312 | 0.86 | CRBN (0.56) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL4450784 | 0.86 | CRBN (0.60) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413886 | 0.85 | CRBN (0.59) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL1413621 | 0.84 | CRBN (0.56) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL21983052 | 0.84 | CRBN (0.57) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL62762 | 0.84 | CRBN (0.59) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL4450383 | 0.83 | IKZF2 (0.47) | CRBNDDB1GSPT1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-9447070-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3061758-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2749559-B1 | 5-substituted isoindoline compounds | CELGENE CORP (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2291365-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-8877780-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885GSPT1 1959/4885 |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885GSPT1 1959/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885DDB1 3649/4885GSPT1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.